Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27416713 | 0.80 | CNR2 (0.40) | KDM4EL3MBTL1 | |
| SCHEMBL12870164 | 0.77 | KDM4E (0.51) | XDHKDM4EALOX15TSHRACMSD | |
| SCHEMBL1143130 | 0.76 | MAPT (0.46) | XDHKDM4ETSHRTDP1 | |
| SCHEMBL1146103 | 0.76 | XDH (0.54) | XDH | |
| SCHEMBL1143188 | 0.76 | ALDH1A1 (0.43) | XDHKDM4EALOX15TSHRACMSD | |
| SCHEMBL19913925 | 0.75 | KDM4E (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1142900 | 0.74 | KDM4E (0.42) | XDHKDM4EALOX15TSHRACMSD | |
| SCHEMBL19913924 | 0.74 | KDM4E (0.42) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL8511267 | 0.74 | KDM4E (0.42) | XDHKDM4EALOX15TSHRACMSD | |
| SCHEMBL19919699 | 0.74 | KDM4E (0.42) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340505-B2 | Type III secretion inhibitors, analogs and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2014-10-30 | — | — | US | disclosed |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | XDH 1715/4885KDM4E 4541/4885ALOX15 3540/4885 |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | XDH 1715/4885KDM4E 4541/4885ALOX15 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.